Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts Posted Apr 9, 2021
Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts Posted Apr 9, 2021
Santen Presents at a Global Cell Therapy Conference - The Cell & Gene Meeting on the Mediterranean Posted Apr 6, 2021
Santen Announces Sponsorship of IBSA Blind Football World Grand Prix for the Second Consecutive Year Posted Mar 12, 2021
Santen Recognized as One of Outstanding Enterprises in 2021 Certified Health and Productivity Management Outstanding Organization (Large Enterprise Category) Posted Mar 12, 2021
Notice of Commencement of Preparation for Transition to a Holding Company Structure through Sole-Share Transfer and Change in Fiscal Year Posted Feb 4, 2021
(Timely Disclosure) Notice of Commencement of Preparation for Transition to a Holding Company and Change in Fiscal Year Posted Feb 4, 2021
Santen and Ube Announces U.S. FDA Acceptance of New Drug Application for STN10117 (DE-117) (JAN: Omidenepag Isopropyl) as a Treatment for Patients with Glaucoma and Ocular Hypertension Posted Feb 2, 2021
Santen and Ube Announces Launch of Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in South Korea Posted Feb 1, 2021
Santen to Hold a Presentation for the 39th Annual J.P. Morgan Healthcare Conference Posted Jan 8, 2021
Santen Joins the Valuable 500 International Initiative Promoting the Active Participation of People with Disabilities Posted Jan 7, 2021
